Ipamorelin 10mg
Ipamorelin – a selective ghrelin receptor agonist, studied for GH release without affecting cortisol. Price and batch analysis.
49.00 EUR · In stock
This product is intended solely for scientific and research use, as well as for use as a reference standard in HPLC analysis, and is not an approved medicinal product. It is not intended for the diagnosis, treatment or prevention of disease in humans or animals. It has not been approved by the FDA, the EMA or any national regulator. The information on this page is provided for scientific information purposes only and does not constitute medical advice, a recommendation for use, or any claim of clinical efficacy or safety.
Ipamorelin – what the peptide is
Ipamorelin is a synthetic pentapeptide belonging to the growth hormone-releasing peptides. Its target is not the GHRH receptor, but the ghrelin receptor – also known as the growth hormone secretagogue receptor.
The molecule is defined as selective because, within the studied ranges, it triggers growth hormone release without appreciably affecting cortisol and prolactin – unlike earlier compounds in the group.
This selectivity is precisely why the peptide is considered separately from GHRP-6 and GHRP-2, which belong to the same family but have a broader hormonal profile.
Mechanism of action
Binding to the ghrelin receptor in the pituitary gland triggers a signaling pathway distinct from that of the GHRH receptor. The two pathways work synergistically, which is the basis for research into their combined activation.
The ghrelin receptor is also present in the hypothalamus, where it is involved in appetite regulation. In Ipamorelin, however, the appetite component is described as mild – a difference compared to GHRP-6, where it is more pronounced.
The selectivity is explained by the molecule's structure, which limits interaction with receptor systems linked to cortisol release.
Research data and observations
Observations measure growth hormone concentrations after administration and compare them with cortisol and prolactin values. This comparison underlies the definition of selectivity.
A separate line of research examines combination with a GHRH analog. Since the two compounds act through different receptors, the question is whether the response exceeds the sum of the individual effects.
A significant part of the data comes from preclinical models and studies with a small number of participants.
When interpreting the published data, the difference between preclinical and clinical conditions should be taken into account. Results from cell cultures and animal models describe a mechanism but do not allow quantitative conclusions for human conditions.
The dose ranges used in preclinical studies are often not directly translatable due to differences in metabolism between species. This limitation is consistently noted in review papers.
Example calculations
The calculations below are purely mathematical examples showing the relationship between the total amount of substance, the volume of solvent, and the resulting concentration. They do not represent a dosing recommendation, administration schedule, or instructions for use.
When dissolving 10 mg with 2 ml bacteriostatic water:
The resulting concentration is 5 mg/ml, with 0.20 ml containing 1 mg of substance.
Example values:
- 0.1 ml = 0.5 mg
- 0.2 ml = 1 mg
- 0.3 ml = 1.5 mg
- 0.4 ml = 2 mg
- 0.5 ml = 2.5 mg
Overview of scientific publications
The literature on selective ghrelin agonists is smaller in volume than that on earlier representatives of the group, as these compounds were described more recently.
Comparisons between individual secretagogues require caution due to differences in receptor selectivity and in the studied ranges.
Safety data from the studies
Among the reported observations are reactions at the injection site and a brief sensation of warmth. The profile is described as more limited compared to earlier compounds in the group.
Long-term controlled studies in humans have not been published.
A general limitation for compounds in this category is the absence of long-term controlled human studies. The available information describes mechanism and short-term observations, not a safety profile for long-term use.
This product is intended exclusively for research purposes. It is not a food, dietary supplement, or medicinal product and is not intended for the diagnosis, treatment, or prevention of any disease.